5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule research compound that functions as a selective, membrane-permeable inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It belongs to a class of low-molecular-weight enzyme inhibitors developed through medicinal-chemistry optimization of the 1-methylquinolinium scaffold. It is important to note at the outset that 5-Amino-1MQ is a synthetic organic small molecule and not a peptide — it has no amino-acid backbone and is defined instead by its chemical structure and its biochemical mechanism class.
Within the research literature, 5-Amino-1MQ is studied as a tool compound for probing the NNMT enzyme and the metabolic pathways it intersects, including nicotinamide adenine dinucleotide (NAD+) biology and S-adenosylmethionine (SAM)-dependent methylation.[1] This article summarizes the published peer-reviewed literature on 5-Amino-1MQ and the broader NNMT-inhibitor class for research-use-only context. 5-Amino-1MQ is classified as a research compound; it has not been approved by the FDA for any therapeutic indication, and all information presented here reflects findings from preclinical and in-vitro studies.
OverviewWhat is 5-Amino-1MQ
5-Amino-1MQ emerged from medicinal-chemistry research aimed at identifying selective small-molecule inhibitors of nicotinamide N-methyltransferase. NNMT is a cytosolic methyltransferase enzyme that has attracted research interest because its expression is elevated in white adipose tissue and liver in certain rodent and human metabolic-disease models, positioning it as a candidate node in metabolic-disease research.[2] The search for pharmacological tools to probe NNMT followed earlier genetic work showing that reducing NNMT expression altered metabolic phenotypes in mice, which created demand for a small-molecule approach that could be applied acutely in research models.[2]
Structurally, 5-Amino-1MQ is classified as a 1-methylquinolinium derivative. The parent scaffold, 1-methylquinolinium (1-MQ), is a quinoline-based heterocyclic cation; the “5-amino” designation indicates an amino substituent at the 5-position of the quinolinium ring system. Structure-activity relationship studies on this scaffold reported that the unsubstituted 1-MQ core inhibits NNMT in the micromolar range, and that small substituents such as methyl or amino groups at certain ring positions are tolerated without loss of binding, whereas bulkier groups reduce affinity due to steric constraints in the enzyme active site.[4] 5-Amino-1MQ is a small molecule with a low molecular weight, in contrast to peptide research compounds, which are chains of amino acids with substantially higher molecular weights.
In the landscape of NNMT-inhibitor research, 5-Amino-1MQ occupies a specific niche. NNMT inhibitors reported in the literature span several chemotype families: nicotinamide-mimetic small molecules, bisubstrate inhibitors that span both the nicotinamide and SAM binding pockets, covalent inhibitors, and quinolinium-based compounds.[4] 5-Amino-1MQ sits within the quinolinium-based, membrane-permeable category — a property that has made it a frequently used tool compound in cell-based and rodent research because it can reach the intracellular compartment where NNMT operates.[1] It was characterized in a 2018 study from a research group at the University of Texas, which described selective and membrane-permeable small-molecule NNMT inhibitors and examined them in diet-induced obese mice.[1] Subsequent publications have used 5-Amino-1MQ and related NNMT inhibitors across additional research domains, including skeletal-muscle stem-cell biology and cell-proliferation studies.[5][10] Other research groups have independently pursued distinct NNMT-inhibitor chemotypes for metabolic-disease research, underscoring that 5-Amino-1MQ is one of several scaffolds under active investigation.[6][8]
ScienceMechanism of Action
The defining biochemical activity of 5-Amino-1MQ is inhibition of the nicotinamide N-methyltransferase enzyme. Understanding its mechanism requires first describing what NNMT does. NNMT catalyzes the transfer of a methyl group from the universal methyl donor S-adenosylmethionine (SAM) onto nicotinamide (the amide form of vitamin B3). This single enzymatic reaction produces two products: 1-methylnicotinamide (also written N1-methylnicotinamide or MNA) and S-adenosylhomocysteine (SAH).[3] Because this reaction simultaneously consumes a nicotinamide molecule and a SAM molecule, NNMT sits at the intersection of two major metabolic systems.
NAD+ salvage pathway. Nicotinamide is a key precursor in the salvage pathway that regenerates NAD+, a cofactor central to cellular redox reactions and to the activity of NAD+-dependent enzymes such as sirtuins. When NNMT methylates nicotinamide, that nicotinamide is diverted away from NAD+ resynthesis and toward excretion as 1-methylnicotinamide.[3] Research has therefore examined whether inhibiting NNMT — for example with 5-Amino-1MQ — can shift the balance of intracellular nicotinamide back toward the NAD+ salvage route. In adipocyte cell-culture systems, treatment with 5-Amino-1MQ has been associated in published work with reduced intracellular 1-methylnicotinamide and increased intracellular NAD+.[1]
SAM methylation cycle. The second arm of the mechanism involves the methyl-donor economy of the cell. Each NNMT reaction consumes a SAM molecule and generates SAH, a product that can feed into homocysteine metabolism. Reviews of NNMT biology describe the enzyme as a regulator of cellular “methylation potential” — the SAM-to-SAH ratio that influences the activity of other methyltransferases, including those acting on DNA and histones.[3] By reducing NNMT flux, an inhibitor such as 5-Amino-1MQ has been studied for its effect on intracellular SAM availability in research models.[3]
The downstream consequences that researchers have characterized follow from these two upstream shifts. Because sirtuin enzymes depend on NAD+, changes in NAD+ availability have been examined as a route through which NNMT modulation may influence mitochondrial and energy-metabolism pathways in cell and animal models.[3] In genetic studies, knockdown of NNMT in white adipose tissue and liver was reported to alter cellular energy expenditure, and the investigators connected this to increased adipose SAM and NAD+ levels and to changes in polyamine-pathway enzyme activity.[2] Pharmacological work with selective NNMT inhibitors has aimed to reproduce aspects of this enzyme-level intervention without genetic manipulation, allowing acute, controlled study of the pathway.[1]
Mechanistic medicinal-chemistry studies have also characterized how quinolinium-class compounds engage the NNMT active site. As nicotinamide-mimetic inhibitors, compounds in this family are understood to compete at or near the nicotinamide-binding pocket of the enzyme; reviews of NNMT inhibitor mechanisms catalogue this alongside bisubstrate and covalent strategies that target the SAM pocket or active-site cysteine residues.[4] It is important to frame all of this in research terms: the published literature characterizes 5-Amino-1MQ as a tool for interrogating NNMT enzymology and the NAD+/SAM axis in defined model systems, and the precise quantitative contributions of each downstream branch remain an active area of investigation.[3][4]
NNMT inhibition shifts the NAD+ salvage balance in adipocyte cultures
In differentiated adipocyte cell-culture systems, published work has associated 5-Amino-1MQ treatment with reduced intracellular 1-methylnicotinamide and increased intracellular NAD+, characterizing the compound as a tool for probing the NAD+ salvage route.
Genetic NNMT knockdown studied in adipose-tissue research models
Genetic work in mice reported that reducing NNMT expression in white adipose tissue and liver altered cellular energy expenditure and was connected to increased adipose SAM and NAD+ levels — the genetic validation that motivated small-molecule tool compounds.
Quinolinium-based, membrane-permeable chemotype as a research tool
5-Amino-1MQ sits within the quinolinium-based, membrane-permeable NNMT-inhibitor category, a property that has made it a frequently used tool compound in cell-based and rodent research because it can reach the intracellular compartment where NNMT operates.
ResearchResearch Context
Research involving 5-Amino-1MQ and the broader NNMT-inhibitor class has concentrated in several overlapping domains. The literature here is comparatively young and small relative to long-studied research compounds, and most published findings derive from cell-culture and rodent models.
Adipocyte and lipid-metabolism research. The most extensively studied domain involves adipose-tissue biology. Interest in NNMT as a research target was substantially shaped by a 2014 study in which knockdown of NNMT in white adipose tissue and liver was examined in mice; the investigators reported that reducing NNMT expression was associated with protection against diet-induced obesity and related metabolic endpoints, and they proposed that NNMT influences cellular energy expenditure.[2] This genetic work motivated the development of small-molecule NNMT inhibitors as research tools. A 2018 study characterized selective, membrane-permeable small-molecule NNMT inhibitors — the chemotype family that includes 5-Amino-1MQ — and examined them in diet-induced obese mice, reporting effects on body weight, white adipose mass, and adipocyte size in that model, with the in-vitro arm of the work using differentiated adipocyte cultures to study effects on adipocyte and lipid metabolism endpoints.[1] Importantly, that study reported no significant change in food intake in the treated animals, which the authors discussed in the context of an energy-metabolism rather than appetite-mediated mechanism.[1]
NAD+ biology and metabolic homeostasis. Because NNMT consumes the NAD+ precursor nicotinamide, NNMT inhibition has been studied as an indirect lever on NAD+ biology. Review literature has synthesized how NNMT links one-carbon (SAM) metabolism, NAD+ availability, and epigenetic regulation, framing the enzyme as a crossroads between cellular metabolism and gene regulation.[3] Studies examining NNMT activity across tissues reported that, as obesity develops in mice, body weight predicts NNMT activity specifically in white adipose tissue and not in other tissues examined — a finding consistent with a tissue-specific role for adipose NNMT in body-weight regulation research.[11] Additional work has characterized how NNMT expression changes during beige adipogenesis, reporting depot-specific dynamic induction of the enzyme in adipose tissue.[12]
Skeletal-muscle and cellular-aging research. A 2019 study examined a small-molecule NNMT inhibitor in the context of skeletal-muscle stem cells, reporting that NNMT inhibition was associated with activation of senescent muscle stem cells and with measures of regenerative capacity in aged-mouse muscle in that model.[5] This work situates NNMT inhibition within cellular and metabolic aging research, where the NAD+ connection is of particular interest because NAD+ levels are reported to decline in various aged tissue models. As with the adipose work, these findings are preclinical and describe model-system endpoints rather than study-subject outcomes.
Parallel medicinal-chemistry programs. Independently of the quinolinium scaffold, other research groups have characterized distinct NNMT-inhibitor chemotypes for metabolic-disease research. A 2018 study described a nicotinamide-analog small-molecule NNMT inhibitor and examined it in diet-induced obese mice with attention to glucose and body-composition endpoints.[6] A 2021 study reported additional novel NNMT inhibitors evaluated in metabolic-disorder research contexts,[8] and a 2022 study described novel tricyclic small-molecule NNMT inhibitors with the same research framing.[7] Beyond metabolic research, NNMT inhibitors have also been examined in cell-proliferation studies; a 2021 study reported anti-proliferative activity of a small-molecule NNMT inhibitor in a cultured cancer cell line.[10] Together these parallel programs indicate that NNMT is a target of broad research interest and that 5-Amino-1MQ is one representative of a larger inhibitor landscape.
Adjacent interventions. Some research has examined NNMT inhibition alongside other variables. A 2022 study examined a reduced-calorie diet combined with NNMT inhibition in diet-induced obese mice and reported effects on the gut microbiome composition in that model, illustrating how NNMT-inhibitor research increasingly intersects with diet and microbiome variables.[9] Across all of these domains, the published evidence is preclinical; no approved therapeutic use exists, and the literature is best read as a characterization of an enzyme target and its tool compounds. Researchers exploring related metabolic pathways may also find the Improved Peptides research overviews on MOTS-c and tesamorelin useful as adjacent entries in the metabolic-research pillar.
QualityPurity and Quality Considerations
For any research compound, analytical quality is foundational to reproducible results — and this is especially true for an enzyme-inhibitor tool compound such as 5-Amino-1MQ. Inhibition assays, intracellular metabolite measurements, and concentration-response characterization all depend on knowing precisely what is in the vial. Residual synthesis intermediates, counter-ion variation, solvent carryover, or unrelated organic impurities can shift apparent potency, introduce off-target effects, or simply make results difficult to reproduce across batches.
Two analytical techniques are central to characterizing a small molecule like 5-Amino-1MQ. High-performance liquid chromatography (HPLC) separates the components of a sample and quantifies chemical purity — the percentage of the material that is the intended compound versus impurities. Mass spectrometry confirms identity by measuring molecular mass, verifying that the compound in the vial matches the expected structure of 5-Amino-1MQ rather than a related or mislabeled substance. Used together, HPLC and mass spectrometry answer the two essential questions a researcher needs settled before an experiment: how pure is it, and is it the right compound.
Improved Peptides supplies 5-Amino-1MQ to an analytical-grade purity standard, with each batch documented on a Certificate of Analysis (COA). The COA reports the measured HPLC purity figure and the mass-spectrometry identity confirmation for that specific lot. Researchers can review the testing standards that describe the analytical methodology applied to every batch, browse batch-specific documentation in the Certificate of Analysis library, and consult the guide on how to read a Certificate of Analysis for help interpreting purity, identity, and analytical data. Verifying the COA for the specific lot in hand is a recommended step in research planning, because purity and identity data are batch-specific rather than generic to the compound.
HandlingStorage and Handling
5-Amino-1MQ is typically supplied as a lyophilized (freeze-dried) solid for research use. Proper storage and handling preserve compound integrity and support reproducible experimental results. The following reflects general good-practice handling for research compounds of this class and is intended strictly for laboratory research preparation contexts.
Lyophilized storage. In its dry, lyophilized form, 5-Amino-1MQ is generally most stable when kept cold, protected from light, and shielded from moisture. Many laboratories store lyophilized research compounds refrigerated for short-term holding or frozen for longer-term storage. Keeping the vial sealed until use limits exposure to atmospheric humidity, which can affect a hygroscopic solid.
Reconstitution for research preparation. When a study design calls for the compound in solution, 5-Amino-1MQ is reconstituted in an appropriate research-grade solvent or buffer selected for the experimental system — for example, a vehicle suitable for cell-culture or in-vitro assay work. Solvent choice and concentration are determined by the requirements of the research protocol. This reconstitution is a laboratory research-preparation step; it is not preparation for human or animal administration, and 5-Amino-1MQ products are not intended for consumption.
Stability after reconstitution. Once in solution, research compounds are generally less stable than in the lyophilized state. Laboratories commonly prepare working solutions shortly before use, store any reconstituted material cold and protected from light, and may aliquot solutions to limit repeated freeze-thaw cycles, which can degrade compound integrity. Documenting reconstitution dates and storage conditions supports data reproducibility. Researchers should follow institutional handling guidance and the documentation accompanying their specific batch.
SummaryConclusion and Open Research Questions
5-Amino-1MQ is a small-molecule, membrane-permeable inhibitor of nicotinamide N-methyltransferase that has been studied as a research tool for probing the NAD+ salvage pathway and the SAM methylation cycle in defined model systems. The published literature — concentrated in adipocyte metabolism, NAD+ biology, metabolic homeostasis, and skeletal-muscle stem-cell research — characterizes how inhibiting NNMT shifts intracellular metabolite balances and associated endpoints in cell-culture and rodent models.
Several research questions remain open. The relative contribution of the NAD+ branch versus the SAM-methylation branch to the metabolic phenotypes observed with NNMT inhibition is not fully resolved. Long-term effects, tissue selectivity, and the comparative behavior of different NNMT-inhibitor chemotypes — quinolinium-based, nicotinamide-mimetic, bisubstrate, and tricyclic — remain areas of active medicinal-chemistry investigation. The relationship between NNMT inhibition and downstream sirtuin and epigenetic pathways also continues to be characterized. Because the body of literature is comparatively young, replication across independent laboratories and model systems is an important ongoing need. No human clinical trial data establish therapeutic use, and 5-Amino-1MQ is not approved by any regulatory agency. For additional research overviews and to explore adjacent compounds, see the Improved Peptides research library, and review the original peer-reviewed studies linked in the references below for independent verification.
Q&AFrequently Asked Questions
What is 5-Amino-1MQ?+
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule research compound classified as a selective, membrane-permeable inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). Structurally it is a 1-methylquinolinium derivative — a low-molecular-weight synthetic organic compound, not a peptide. It is studied in preclinical research models and has not been approved by the FDA for any therapeutic indication.
How is 5-Amino-1MQ researched?+
Published studies have examined 5-Amino-1MQ primarily in cell-culture systems and rodent models. In vitro work has used differentiated adipocyte cultures to characterize effects on NNMT enzyme activity and intracellular metabolite levels, while in vivo work has used diet-induced obese mice to study effects on adipose tissue and body composition endpoints. All findings discussed are derived from preclinical and in-vitro research.
What testing does Improved Peptides perform on 5-Amino-1MQ?+
Each batch of 5-Amino-1MQ is analyzed by high-performance liquid chromatography (HPLC) to quantify chemical purity and by mass spectrometry to confirm compound identity against the expected molecular mass. Results are documented on a batch-specific Certificate of Analysis available through the Improved Peptides COA Library, consistent with the published testing standards.
What is the purity standard for 5-Amino-1MQ?+
Improved Peptides supplies 5-Amino-1MQ to an analytical-grade purity standard verified by HPLC, with mass-spectrometry identity confirmation. High analytical purity matters in research contexts because residual synthesis impurities or solvent carryover can confound enzyme-inhibition assays and metabolite measurements. The batch Certificate of Analysis reports the measured purity figure for each lot.
Where can I read more about 5-Amino-1MQ research?+
The Improved Peptides Research Library hosts research overviews for the compounds in the catalog, including related metabolic-pillar entries on MOTS-c and tesamorelin. The reference list at the end of this article links to the original peer-reviewed studies on PubMed for independent verification, which is the recommended primary source for NNMT-inhibitor research.
Why is 5-Amino-1MQ described as an NNMT inhibitor rather than a peptide?+
5-Amino-1MQ is a small-molecule organic compound — a 1-methylquinolinium derivative — with a low molecular weight and no amino-acid backbone, so it is not a peptide. It is categorized by its mechanism class: it inhibits the enzyme nicotinamide N-methyltransferase. Describing it as a small-molecule NNMT inhibitor reflects both its chemical structure and the biochemical pathway studied in the published literature.
What metabolic pathways have been studied with NNMT inhibition?+
Research on NNMT inhibition has focused on two intersecting pathways: the NAD+ salvage pathway, because NNMT consumes nicotinamide that would otherwise be available for NAD+ synthesis, and the S-adenosylmethionine (SAM) methylation cycle, because NNMT consumes SAM as a methyl donor. Studies have characterized how altering NNMT activity shifts intracellular NAD+, SAM, and 1-methylnicotinamide levels in adipocyte and other model systems.
About this research overview. This article summarizes published peer-reviewed literature on this compound for research-use-only context. Improved Peptides products are research compounds and are not drugs, supplements, or foods. They are not intended for human or animal consumption. Citations link to the original studies for independent verification.